Treatment of abiraterone-resistant prostate cancer cells with indomethacin, a small-molecule AKR1C3 inhibitor, restores and even increases the sensitivity of prostate cancer cells to abiraterone therapy, while reducing intracrine androgen levels and AR transcriptional activity15,.30 This evidence concerns the gene AR and prostate cancer.